SecBot SecBot
Biotech Drug Report Generated Jul 13, 2026

ILUVIEN

ANIP·ANI Pharmaceuticals, Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved (Phase 4 SYNCHRONICITY data reported July 2026)
Time to market
Already approved and marketed (FDA-approved September 2014 for DME; label expanded March 2025 for NIU-PS uveitis)
Why 3/10
ILUVIEN is already FDA-approved and commercialized with no pending PDUFA or pivotal readout in the next ~12 months. The recently announced positive Phase 4 SYNCHRONICITY data (July 13, 2026) is a commercial-support data readout, not a binary regulatory catalyst. As one product in ANI's diversified portfolio (~$75M of $883M total 2025 revenue), ILUVIEN alone cannot drive a major share-price move.
Actionable Insight NEUTRAL

ILUVIEN is a steady commercial asset within ANI's larger Rare Disease transition story. The positive July 2026 Phase 4 SYNCHRONICITY data supports the uveitis label expansion's real-world use, but the stock's bigger drivers are Cortrophin Gel growth and overall margin expansion. Watch quarterly sales trends for ILUVIEN against the $78M-$83M 2026 guidance.

Price Chart

Loading chart...

Executive Summary

ILUVIEN is a 36-month sustained-release corticosteroid intravitreal implant for diabetic macular edema (DME) and chronic non-infectious posterior uveitis (NIU-PS). Originally developed by Alimera Sciences and pSivida, it was acquired by ANI Pharmaceuticals in September 2024 for ~$381M. It generated $74.9M in net revenue for ANI in 2025 and is guided for $78M-$83M in 2026. ILUVIEN occupies a niche position behind anti-VEGF standard-of-care therapies (Eylea, Lucentis) for DME patients who have previously tolerated corticosteroids. In March 2025, the FDA approved a label expansion to include NIU-PS. Very recent Phase 4 SYNCHRONICITY data (July 13, 2026) showed positive six-month efficacy in uveitis, supporting commercial uptake. The drug faces competition from other corticosteroid implants (Ozurdex, YUTIQ) and market access headwinds with Medicare patients.

How It Works

ILUVIEN is a tiny, sustained-release corticosteroid implant injected into the vitreous gel of the eye. It delivers a steady, low dose of fluocinolone acetonide (a steroid) for up to 36 months to reduce inflammation and swelling in the retina, treating diabetic macular edema and chronic uveitis. A single injection replaces the need for frequent eye injections.

Trial Status

ILUVIEN is FDA-approved for two indications. The Phase 4 SYNCHRONICITY trial (single-arm, open-label) met both co-primary endpoints at 6 months, BCVA improved 3.6 ETDRS letters (p≤0.0077) and CST fell 157.5 microns (p<0.0001), with full results to be presented at a future medical meeting. The NEW DAY Phase 4 trial in DME was published in Ophthalmology journal in April 2026.

The Two-Sided Case

▲ Bull Case6
ILUVIEN is an already-approved, revenue-generating asset contributing $74.9M in 2025 net revenue, with 2026 guidance of $78M-$83M suggesting growth (source: ANI Q4 2025 earnings via fool.com).
The March 2025 FDA label expansion to chronic non-infectious uveitis (NIU-PS) opens a second addressable patient population beyond DME (source: globenewswire.com).
Positive Phase 4 SYNCHRONICITY data (July 13, 2026) met both co-primary endpoints, supporting real-world efficacy in uveitis and potentially driving physician adoption (source: yahoo.com).
ANI eliminated a 3.125% perpetual royalty on ILUVIEN and YUTIQ via a $17.25M buyout, improving per-unit margins going forward (source: nasdaq.com).
Commercial synergies with ANI's existing ophthalmology sales force (also selling Cortrophin Gel and YUTIQ) should drive operational leverage (source: roi-nj.com).
NEW DAY trial results published in Ophthalmology journal reinforce ILUVIEN's positioning in the DME treatment sequence (source: biospace.com).
▼ Bear Case5
ILUVIEN is a niche product in DME, indicated only for patients previously treated with corticosteroids who did not have an intraocular pressure rise, limiting its addressable market vs. first-line anti-VEGF therapies like Eylea/Regeneron and Lucentis/Roche (source: healio.com).
Market access challenges (Medicare funding constraints for patient assistance programs) impacted Q1 2025 retina asset revenues; turnover in the ophthalmology sales team further pressured sales (source: SEC filing via sec.gov).
ILUVIEN is a mature product (approved since 2014) facing competition from other corticosteroid implants including ANI's own YUTIQ and AbbVie's Ozurdex, as well as newer anti-VEGF agents like Vabysmo (source: researchandmarkets.com).
As only ~8.5% of ANI's $883M total 2025 revenue, ILUVIEN alone is unlikely to be a needle-moving stock catalyst, Cortrophin Gel and the generics segment are larger value drivers (source: fool.com earnings transcript).
Safety liabilities of corticosteroid implants include cataract formation and increased intraocular pressure, which require monitoring and may limit adoption (source: pharmanow.live).

Upcoming Catalysts

  • Commercial sales trajectory: Q2 2026 ILUVIEN net revenue (estimated early August 2026) vs. $78M-$83M full-year guidance.
  • Full SYNCHRONICITY Phase 4 results presented at an upcoming medical meeting (date TBD).
  • Potential further payer coverage expansion for the NIU-PS indication as Medicare and commercial policies continue to update.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

ANI Pharmaceuticals, Inc. Press Release ANIP ·Originating report

Sources · 11

Hover a chip for the title
1 nasdaq.com2 fool.com3 globenewswire.com4 nasdaq.com5 healio.com6 drugs.com7 biospace.com8 roi-nj.com9 dailymed.nlm.nih.gov10 clinicaltrialsarena.com11 ainvest.com